Biosimilar: Analytics&Market – An Article from VelaLabs

April 2020: The deep experience of VelaLabs with biosimilars is now demonstrated by a review article in the journal “Medical Research Archives”. The review gives a short but comprehensive overview about selected biosimilars. Adalimumab, the best-selling pharmaceutical product world-wide, is analyzed in more detail including a competitive field and the portfolio of methods required for analytical assessment. Markets not only in developed and highly regulated countries but also in other regions are discussed.

Please find the article here.

If you have any questions or concerns, please contact us via our general email velabd@vela-labs.at or give us a phone call at +43 189 059 7911.